Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Fisogatinib + Sugemalimab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Fisogatinib | BLU554|BLU-554 | FGFR4 Inhibitor 10 | Fisogatinib (BLU-554) binds to and inhibits FGFR4 (a receptor for FGF19), potentially resulting in decreased proliferation of FGFR4 and FGF19-expressing tumor cells (PMID: 29547556, PMID: 31575540, PMID: 31575541). | |
| Sugemalimab | Cejemly | WBP3155|CS1001 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | Sugemalimab (CS1001) is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|